The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Patents, Royalties, Other Intellectual Property - I received royalities for authoring textbook chapters related to surgical pathology/medicine for Elsevier publishing company.
Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant non-small cell lung cancer (NSCLC).
 
Alissa Jamie Cooper
No Relationships to Disclose
 
Alona Muzikansky
No Relationships to Disclose
 
Jochen K Lennerz
No Relationships to Disclose
 
Mari Mino-Kenudson
Honoraria - BMS; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; H3 Biomedicine
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - Elsevier
 
Yin P Hung
No Relationships to Disclose
 
Zofia Piotrowska
Consulting or Advisory Role - Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo Europe GmbH; Janssen; Jazz Pharmaceuticals; Takeda
Research Funding - Abbvie (Inst); ARIAD/Takeda (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen Oncology (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune
 
Ibiayi Dagogo-Jack
Honoraria - American Academic Health System; American Society of Clinical Oncology; Creative Educational Concepts; DAVA Oncology; Medscape; OncLive/MJH Life Sciences; Total Health Conferencing
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; BostonGene; Catalyst Pharmaceuticals; Genentech; Janssen; Novocure; Pfizer; Sanofi; Syros Pharmaceuticals; Xcovery
Research Funding - Array BioPharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst); Vivace Therapeutics (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Pfizer
 
Lecia V. Sequist
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Janssen Oncology; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Delfi Diagnostics (Inst); Genentech (Inst); Johnson & Johnson (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; ITeos Therapeutics; Jounce Therapeutics; Karyopharm Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Abbvie; Daichii Sankyo; Daichii Sankyo; EMD Serono/Merck; EMD Serono/Merck; Novartis
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)